Axsome Therapeutics, Inc. has recently announced the initiation of the FOCUS Phase 3 trial for solriamfetol, a promising investigational treatment for Attention Deficit Hyperactivity Disorder (ADHD) in adults. The primary objective of this trial is to evaluate the efficacy and safety of solriamfetol in approximately 450 adult patients over a duration of 6 weeks. Solriamfetol belongs to the class of dopamine and norepinephrine reuptake inhibitors, and it has exhibited potential as a viable treatment option for individuals with ADHD.
Attention Deficit Hyperactivity Disorder (ADHD) is a chronic neurobiological disorder characterized by symptoms such as inattention, hyperactivity, and impulsivity. It affects both children and adults, with an estimated 11.4 million adults diagnosed with ADHD in the United States alone. This condition can have substantial impacts on cognitive functioning and daily activities, resulting in difficulties with attention span, planning abilities, problem-solving skills, working memory, and behavioral control.